Cargando…

Novel protocol to establish the myocardial infarction model in rats using a combination of medetomidine-midazolam-butorphanol (MMB) and atipamezole

BACKGROUND: Myocardial infarction (MI) is one of the most common cardiac problems causing deaths in humans. Previously validated anesthetic agents used in MI model establishment are currently controversial with severe restrictions because of ethical concerns. The combination between medetomidine, mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Farag, Ahmed, Mandour, Ahmed S., Hamabe, Lina, Yoshida, Tomohiko, Shimada, Kazumi, Tanaka, Ryou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760920/
https://www.ncbi.nlm.nih.gov/pubmed/36544554
http://dx.doi.org/10.3389/fvets.2022.1064836
_version_ 1784852590191706112
author Farag, Ahmed
Mandour, Ahmed S.
Hamabe, Lina
Yoshida, Tomohiko
Shimada, Kazumi
Tanaka, Ryou
author_facet Farag, Ahmed
Mandour, Ahmed S.
Hamabe, Lina
Yoshida, Tomohiko
Shimada, Kazumi
Tanaka, Ryou
author_sort Farag, Ahmed
collection PubMed
description BACKGROUND: Myocardial infarction (MI) is one of the most common cardiac problems causing deaths in humans. Previously validated anesthetic agents used in MI model establishment are currently controversial with severe restrictions because of ethical concerns. The combination between medetomidine, midazolam, and butorphanol (MMB) is commonly used in different animal models. The possibility of MMB combination to establish the MI model in rats did not study yet which is difficult because of severe respiratory depression and delayed recovery post-surgery, resulting in significant deaths. Atipamezole is used to counter the cardiopulmonary suppressive effect of MMB. OBJECTIVES: The aim of the present study is to establish MI model in rats using a novel anesthetic combination between MMB and Atipamezole. MATERIALS AND METHODS: Twenty-five Sprague Dawley (SD) rats were included. Rats were prepared for induction of the Myocardial infarction (MI) model through thoracotomy. Anesthesia was initially induced with a mixture of MMB (0.3/5.0/5.0 mg/kg/SC), respectively. After endotracheal intubation, rats were maintained with isoflurane 1% which gradually reduced after chest closing. MI was induced through the left anterior descending (LAD) artery ligation technique. Atipamezole was administered after finishing all surgical procedures at a dose rate of 1.0 mg/kg/SC. Cardiac function parameters were evaluated using ECG (before and after atipamezole administration) and transthoracic echocardiography (before and 1 month after MI induction) to confirm the successful model. The induction time, operation time, and recovery time were calculated. The success rate of the MI model was also calculated. RESULTS: MI was successfully established with the mentioned anesthetic protocol through the LAD ligation technique and confirmed through changes in ECG and echocardiographic parameters after MI. ECG data was improved after atipamezole administration through a significant increase in heart rate (HR), PR Interval, QRS Interval, and QT correction (QTc) and a significant reduction in RR Interval. Atipamezole enables rats to recover voluntary respiratory movement (VRM), wakefulness, movement, and posture within a very short time after administration. Echocardiographic ally, MI rats showed a significant decrease in the left ventricular wall thickness, EF, FS, and increased left ventricular diastolic and systolic internal diameter. In addition, induction time (3.440 ± 1.044), operation time (29.40 ± 3.663), partial recovery time (10.84 ± 3.313), and complete recovery time (12.36 ± 4.847) were relatively short. Moreover, the success rate of the anesthetic protocol was 100%, and all rats were maintained for 1 month after surgery with a survival rate of 88%. CONCLUSION: Our protocol produced a more easy anesthetic effect and time-saving procedures with a highly successful rate in MI rats. Subcutaneous injection of Atipamezole efficiently counters the cardiopulmonary side effect of MMB which is necessary for rapid recovery and subsequently enhancing the survival rate during the creation of the MI model in rats.
format Online
Article
Text
id pubmed-9760920
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97609202022-12-20 Novel protocol to establish the myocardial infarction model in rats using a combination of medetomidine-midazolam-butorphanol (MMB) and atipamezole Farag, Ahmed Mandour, Ahmed S. Hamabe, Lina Yoshida, Tomohiko Shimada, Kazumi Tanaka, Ryou Front Vet Sci Veterinary Science BACKGROUND: Myocardial infarction (MI) is one of the most common cardiac problems causing deaths in humans. Previously validated anesthetic agents used in MI model establishment are currently controversial with severe restrictions because of ethical concerns. The combination between medetomidine, midazolam, and butorphanol (MMB) is commonly used in different animal models. The possibility of MMB combination to establish the MI model in rats did not study yet which is difficult because of severe respiratory depression and delayed recovery post-surgery, resulting in significant deaths. Atipamezole is used to counter the cardiopulmonary suppressive effect of MMB. OBJECTIVES: The aim of the present study is to establish MI model in rats using a novel anesthetic combination between MMB and Atipamezole. MATERIALS AND METHODS: Twenty-five Sprague Dawley (SD) rats were included. Rats were prepared for induction of the Myocardial infarction (MI) model through thoracotomy. Anesthesia was initially induced with a mixture of MMB (0.3/5.0/5.0 mg/kg/SC), respectively. After endotracheal intubation, rats were maintained with isoflurane 1% which gradually reduced after chest closing. MI was induced through the left anterior descending (LAD) artery ligation technique. Atipamezole was administered after finishing all surgical procedures at a dose rate of 1.0 mg/kg/SC. Cardiac function parameters were evaluated using ECG (before and after atipamezole administration) and transthoracic echocardiography (before and 1 month after MI induction) to confirm the successful model. The induction time, operation time, and recovery time were calculated. The success rate of the MI model was also calculated. RESULTS: MI was successfully established with the mentioned anesthetic protocol through the LAD ligation technique and confirmed through changes in ECG and echocardiographic parameters after MI. ECG data was improved after atipamezole administration through a significant increase in heart rate (HR), PR Interval, QRS Interval, and QT correction (QTc) and a significant reduction in RR Interval. Atipamezole enables rats to recover voluntary respiratory movement (VRM), wakefulness, movement, and posture within a very short time after administration. Echocardiographic ally, MI rats showed a significant decrease in the left ventricular wall thickness, EF, FS, and increased left ventricular diastolic and systolic internal diameter. In addition, induction time (3.440 ± 1.044), operation time (29.40 ± 3.663), partial recovery time (10.84 ± 3.313), and complete recovery time (12.36 ± 4.847) were relatively short. Moreover, the success rate of the anesthetic protocol was 100%, and all rats were maintained for 1 month after surgery with a survival rate of 88%. CONCLUSION: Our protocol produced a more easy anesthetic effect and time-saving procedures with a highly successful rate in MI rats. Subcutaneous injection of Atipamezole efficiently counters the cardiopulmonary side effect of MMB which is necessary for rapid recovery and subsequently enhancing the survival rate during the creation of the MI model in rats. Frontiers Media S.A. 2022-12-05 /pmc/articles/PMC9760920/ /pubmed/36544554 http://dx.doi.org/10.3389/fvets.2022.1064836 Text en Copyright © 2022 Farag, Mandour, Hamabe, Yoshida, Shimada and Tanaka. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Farag, Ahmed
Mandour, Ahmed S.
Hamabe, Lina
Yoshida, Tomohiko
Shimada, Kazumi
Tanaka, Ryou
Novel protocol to establish the myocardial infarction model in rats using a combination of medetomidine-midazolam-butorphanol (MMB) and atipamezole
title Novel protocol to establish the myocardial infarction model in rats using a combination of medetomidine-midazolam-butorphanol (MMB) and atipamezole
title_full Novel protocol to establish the myocardial infarction model in rats using a combination of medetomidine-midazolam-butorphanol (MMB) and atipamezole
title_fullStr Novel protocol to establish the myocardial infarction model in rats using a combination of medetomidine-midazolam-butorphanol (MMB) and atipamezole
title_full_unstemmed Novel protocol to establish the myocardial infarction model in rats using a combination of medetomidine-midazolam-butorphanol (MMB) and atipamezole
title_short Novel protocol to establish the myocardial infarction model in rats using a combination of medetomidine-midazolam-butorphanol (MMB) and atipamezole
title_sort novel protocol to establish the myocardial infarction model in rats using a combination of medetomidine-midazolam-butorphanol (mmb) and atipamezole
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760920/
https://www.ncbi.nlm.nih.gov/pubmed/36544554
http://dx.doi.org/10.3389/fvets.2022.1064836
work_keys_str_mv AT faragahmed novelprotocoltoestablishthemyocardialinfarctionmodelinratsusingacombinationofmedetomidinemidazolambutorphanolmmbandatipamezole
AT mandourahmeds novelprotocoltoestablishthemyocardialinfarctionmodelinratsusingacombinationofmedetomidinemidazolambutorphanolmmbandatipamezole
AT hamabelina novelprotocoltoestablishthemyocardialinfarctionmodelinratsusingacombinationofmedetomidinemidazolambutorphanolmmbandatipamezole
AT yoshidatomohiko novelprotocoltoestablishthemyocardialinfarctionmodelinratsusingacombinationofmedetomidinemidazolambutorphanolmmbandatipamezole
AT shimadakazumi novelprotocoltoestablishthemyocardialinfarctionmodelinratsusingacombinationofmedetomidinemidazolambutorphanolmmbandatipamezole
AT tanakaryou novelprotocoltoestablishthemyocardialinfarctionmodelinratsusingacombinationofmedetomidinemidazolambutorphanolmmbandatipamezole